Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Novel cardiovascular therapeutics have the potential to improve health outcomes, but financial toxicity from high out-of-pocket costs can limit the reach of these medications and worsen existing health disparities. Understanding the phenomenon of financial toxicity in treating cardiovascular disease is crucial to achieving health equity.
Three randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.
In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.
In the REDUCE-AMI trial, the use of β-blockers in patients with acute myocardial infarction (MI) who have undergone early coronary angiography and have a preserved left ventricular ejection fraction did not reduce the risk of death or new MI compared with no β-blocker use.
Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.
Treatment for periodontal disease might reduce the recurrence of atrial fibrillation (AF) in patients undergoing ablation, suggesting that periodontitis is a modifiable risk factor for AF.
Findings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural myocardial perfusion.
In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve.
According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.
A new study identifies a hormone that is secreted by the gut in response to cholesterol absorption and can inhibit cholesterol synthesis in the liver, which prevents an increase in circulating cholesterol levels.
After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells.
In this Tools of the Trade article, Trivett discusses the potential of long-read sequencing in generating high-quality reference genomes of animal models of cardiovascular disease.
In this Review, the authors discuss the latest insights on RNA-binding proteins and RNA biology and appraise them in the context of cardiovascular research, summarizing the progress in our understanding of the involvement of RNA-binding proteins in cardiac biology and disease.
Cardiovascular autonomic dysfunction (CVAD) is a malfunction of the autonomic control of circulatory homeostasis and is an important component of post-COVID-19 syndrome. In this Review, Fedorowski and colleagues define the major forms of CVAD (including postural orthostatic tachycardia syndrome), and discuss the aetiology, diagnosis and management of post-COVID-19 syndrome-associated CVAD.
In this Review, Guzik and colleagues discuss immune and inflammatory mechanisms of hypertension, including upstream regulators and downstream effectors as well as the complex interplay between the immune system, blood pressure regulation and end-organ damage, which can help to identify new targets for therapeutic interventions.
In this Review, Bosworth and colleagues describe the causes of medication non-adherence, discuss interventions that have been clinically shown to improve adherence and identify areas for future research.
